| Authors: |
Richardson PG; aJerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Perrot A; bCHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France., San-Miguel J; cCancer Center Clínica Universidad de Navarra, Navarra, CCUN, CIMA,IDISNA, CIBER-ONC, Pamplona, Spain., Beksac M; dDepartment of Hematology, Ankara University, Ankara, Turkey., Spicka I; eGeneral Faculty Hospital, Prague, Czech Republic.; fFirst Faculty of Medicine, Charles University, Prague, Czech Republic., Leleu X; gService d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France., Schjesvold F; hOslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway.; iKG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Moreau P; jHematology Department, CHU Nantes, Nantes, France., Dimopoulos MA; kDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.; lDepartment of Medicine, Korea University, Seoul, South Korea., Huang SY; mDepartment of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Minarik J; nDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc,Olomouc, Czech Republic., Cavo M; ooIRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, and the Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy., Prince HM; pImmunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia., Anderson KC; hOslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway. |
